Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

This study is testing two immunotherapy drugs — iparomlimab and tuvonralimab — combined with standard chemoradiation therapy for women with locally advanced cervical cancer. The drugs help the immune system recognize and attack cancer cells. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have been diagnosed with cervical cancer confirmed by biopsy (squamous cell, adenocarcinoma, or adenosquamous type) related to HPV - Your cancer is at stage III–IVA and has not spread to distant organs - You are in good overall health (ECOG score 0 or 1) - Your kidneys, liver, and blood counts are within acceptable ranges - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have another type of cervical cancer not listed above - Your cancer has spread to distant organs (stage IVB) - You have serious autoimmune conditions - You are pregnant or breastfeeding - You have had prior radiation to the pelvis or prior systemic therapy for cervical cancer Talk to your doctor to see if this trial is right for you.